Concurrent chemotherapy and radiotherapy for head and neck cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer54, 594–606 (1993).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur. J. Cancer38, 223–230 (2002).
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62, 7350–7356 (2002).
   PubMed Web of Science ®Google Scholar
• Wadsley JC, Bentzen SM. Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.60(5), 1405–1409 (2004).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Maitre ALL, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int. J. Radiat. Oncol. Biol. Phys.69(2 Suppl.), S112–S114, (2007).
   PubMed Web of Science ®Google Scholar
• Soo KC, Tan EH, Wee J et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br. J. Cancer93(2), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol.21(1), 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med.349(22), 2091–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere A, Maor M, Weber RS et al. Long-term results of Intergroup RTOG 91-11: a Phase III trial to preserve the larynx–induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Denis F, Garaud P, Bardet E et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J. Clin. Oncol.22, 69–76 (2004).
   PubMed Web of Science ®Google Scholar
• Limaye SA, Nissel-Horowitz S, Caramalis A et al. Concurrent chemoradiotherapy with weekly platinum for patients with unresectable/locally advanced SCCHN and comorbidities. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PGS et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J. Clin. Oncol.16(4), 1310–1317 (1998).
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PGS et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients (pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study: final report. Presented at: 37th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA, USA, 12–15 May 2001.
   Google Scholar
• Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol.23(27), 6730–6738 (2005).
   PubMed Web of Science ®Google Scholar
• Chan TC, Leung SF, Ngan RKC et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst.97(7) 536–539 (2005).
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Leemans CR, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol.22(22), 4604–4612 (2004).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am. J. Clin. Oncol.25(3), 219–223 (2002).
   PubMedGoogle Scholar
• Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int. J. Radiat. Oncol. Biol. Phys.64(1), 47–56 (2006).
   PubMed Web of Science ®Google Scholar
• Yang AK, Liu TR, Guo X et al. Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi43(3), 218–223 (2008).
   PubMedGoogle Scholar
• Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys.53(1), 12–22 (2002).
   PubMed Web of Science ®Google Scholar
• Wolden SL, Chen WC, Pfister DG et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: an update of the Memorial Sloan–Kettering experience. Int. J. Radiat. Oncol. Biol. Phys.64(1), 57–62 (2006).
   PubMed Web of Science ®Google Scholar
• Lee N, Harris J, Garden AS et al. Phase II multi-institutional study of intensity modulated radiation therapy (IMRT) ± chemotherapy for nasopharyngeal (NPC) carcinoma: preliminary clinical results of RTOG 0225. Presented at: 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Boston, MA, USA, 21–25 September 2008.
   Google Scholar
• Seiwert TY, Haraf DJ, Cohen EE. A Phase I study of bevacizumab with fluorouracil and hydroxyurea with concomitant radiotherapy for poor prognosis head and neck cancer. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.350(19), 1945–1952 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med.350(19), 1937–1944 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA et al. Long-term survival results of a Phase III Intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. radiochemotherapy for resectable high risk squamous cell carcinoma of the head and neck. Presented at: 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Philadelphia, PA, USA, 5–9 November 2006.
   Google Scholar
• Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck27(10), 843–850 (2005).
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat.Oncol. Biol. Phys.48(1), 7–16 (2000).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet368(9537), 843–854 (2006).
   PubMed Web of Science ®Google Scholar
• Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.338(25), 1798–1804 (1998).
   PubMed Web of Science ®Google Scholar
• Kasibhatla M, Prosnitz LR, Fisher SR et al. Hyperfractionated radiotherapy versus hyperfractionated radiotherapy and concomitant chemotherapy in locally advanced head and neck cancer. Presented at: 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Los Angeles, CA, USA, 28 October–1 November 2007.
   Google Scholar
• Budach V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil–mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J. Clin. Oncol.23(6), 1125–1135 (2005).
   PubMed Web of Science ®Google Scholar
• Budach VGF, Poettgen C, Baumann M et al. Mitomycin-C and 5-fluoro-uracil containing chemotherapy with concurrent hyperfractionated accelerated radiotherapy (C-HART) of 70.6 Gy is more effective than dose escalated HART of 77.6 Gy alone – 10 year results of the German multicenter Phase III randomized trial (ARO 95-06). Presented at: 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Los Angeles, CA, USA, 28 October–1 November 2007.
   Google Scholar
• Budach W, Hehr T, Budach V et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer6(1), 28 (2006).
   PubMed Web of Science ®Google Scholar
• Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.50(5), 1161–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Garden AS, Harris J, Trotti A et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a Phase II trial of the Radiation Therapy Oncology Group (RTOG 99–14). Int. J. Radiat. Oncol. Biol. Phys.71(5), 1351–1355 (2008).
   PubMed Web of Science ®Google Scholar
• Ang K, Pajak T, Rosenthal DI et al. A Phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of compliance and toxicity. Presented at: 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Los Angeles, CA, USA, 28 October–1 November 2007.
   Google Scholar
• Bourhis J, Sire C, Lapeyre M et al. Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: results of a Phase III randomized trial. Presented at: 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Boston, MA, USA, 21–25 September 2008.
   Google Scholar
• Pryor DI, Porceddu SV, Burmeister BH et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother. Oncol. DOI: 10.1016/j.radonc.2008.09.018 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Giro C, Berger B, Bölke E et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother. Oncol. DOI: 10.1016/j.radonc.2008.09.007 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Kuhnt T, Sandner A, Wendt TG et al. Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a Phase I dose escalation trial. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Kubicek GJ, Machtay M, Axelrod RA et al. Phase I trial of bortezomib (VELCADE), cisplatin and radiotherapy for advanced head and neck cancer. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Wirth LJ, Posner MR, Tishler RB et al. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Wanebo HJ, Ghebremichael M, Burtness B et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Savvides P, Greskovich J, Bokar JA et al. Phase II study of bevacizumab with docetaxel and radiation in locally advanced head and neck squamous cell cancer. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Ma BB, Leung SF, Kam MK et al. A Phase II study of concurrent cetuximab–cisplatin and intensity modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Langer CJ, Lee JW, Patel UA et al. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357(17), 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357(17), 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar